1 Min Read
* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.